Core Viewpoint - Company reported a revenue of 19.22 billion yuan for 2024, marking a year-on-year growth of 10.21%, and a net profit of 676 million yuan, up 45.18% from the previous year [1][2] Group 1: Financial Performance - The company's net profit attributable to shareholders reached 676 million yuan, with a growth rate of 45.18% [1][2] - The net profit after excluding non-recurring gains and losses was 531 million yuan, reflecting a year-on-year increase of 14.71% [1][2] - The chemical and health sectors generated revenues of 17.37 billion yuan and 850 million yuan, respectively, with growth rates of 11.62% and a decline of 12.39% [2] Group 2: Business Strategy - Company focuses on a dual business model of "chemical + health," leveraging vertical integration to enhance its industry platform [4][6] - The strategy includes "New Materials +" for precise layout in the chemical industry and "Collagen +" for multi-dimensional development in the health sector [2][6] - Company aims to enhance its global presence by initiating preparations for H-share issuance and listing [7] Group 3: Market Position and Future Plans - Company is recognized as a leading player in the domestic chemical new materials industry and has been expanding its overseas market presence [6][7] - The company plans to discuss specific details regarding the H-share issuance with relevant intermediaries [7] - The 2024 profit distribution plan includes a cash dividend of 2.8 yuan per 10 shares, totaling approximately 74.2 million yuan [7][8]